| Name | Title | Contact Details |
|---|
Tarrytown Expocare Pharmacy is a specialized long-term care pharmacy dedicated to serving individuals with intellectual and developmental disabilities (IDD) and behavioral health needs. The company operates across 30 U.S. states with ten physical locations, providing institutional pharmacy services to group homes, foster families, and residential care facilities. Tarrytown Expocare focuses on efficiency and safety, offering innovative solutions like color-coded blister packs to simplify medication administration. The pharmacy provides a range of services, including medication management, clinical collaboration, compliance support, and ongoing training for caregivers and nurses. Their secure online portal allows for 24/7 access to manage prescriptions and care coordination. Tarrytown Expocare emphasizes person-centric care and regulatory compliance, aiming to improve outcomes for vulnerable populations through reliable medication delivery and collaborative pharmacy solutions.
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.
Benjamin Biomedical Inc is a St Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.